(MedPage Today) — The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn’t effective enough. (Source: MedPage Today Psychiatry)
Suboxone Maker Pulls Pills in Favor of Film
Next post: Reckitt withdraws Suboxone over abuse